Lightbits Labs Launches Industry’s First NVMe/TCP Clustered Storage Solution
11.12.2019 16:00:00 EET | Business Wire | Press release
Lightbits Labs, the leader in NVMe™ over TCP (NVMe/TCP) software-defined disaggregated storage, today has advanced its software solution, LightOS, to deliver the first NVMe/TCP clustered storage solution.
With more companies moving away from direct attached storage (DAS), and with storage requirements typically growing far faster than compute requirements, both public-cloud providers and private-cloud builders are looking for ways to separate storage and compute so each can scale separately. One of the limiting factors to scaling disaggregated storage, however, is the need for high availability across clusters of storage and compute. Lightbits LightOS delivers the availability, flexibility and efficiency of hyperscale cloud infrastructure to on-premise data centers.
LightOS is now the first NVMe/TCP storage solution that protects against data loss and avoids service interruptions at scale. In the presence of server, storage, or network failures, LightOS maximizes operational efficiency, ensuring applications continue working in the presence of failures, and failover is handled automatically, keeping data fully consistent and available.
The average cost of IT downtime is enormous. According to Gartner, the average loss is $5,600 per minute. This can add up to more than half a million dollars lost per hour at the higher end.
“At cloud scale, everything fails, so we built LightOS to capture all the benefits of disaggregated storage while providing exceptional durability and availability to prevent service disruption,” said Kam Eshghi, Chief Strategy Officer at Lightbits Labs.
For cloud-native applications, access to available, performant and easily deployable infrastructure is key to business agility and application experience, at any scale - regardless of whether you deploy five nodes, five hundred nodes, or thousands of nodes.
Installed on commodity servers in large-scale data centers, LightOS is optimized for I/O intensive compute clusters, such as Cassandra, MySQL, MongoDB, and time series databases. With end-to-end NVMe, LightOS delivers high performance and consistently low latency. The result is a 10X increase in storage reliability and 50% decrease in total cost of ownership (TCO). As a standard-based, target-only solution that does not require installing any proprietary software on the client side, the ease of deployment at scale is unmatched. LightOS is built to run in your existing data center, requiring no changes to application servers or your network infrastructure, so that deploying it at scale is a breeze.
As LightOS provides highly available, flexible, and efficient disaggregated storage, application teams can focus their efforts on developing new services to achieve their business goals, while lowering spend and delivering high performance.
LightOS provides the following additional benefits:
- Software-defined disaggregated storage for cloud data centers delivering similar performance as direct-attached NVMe SSDs and up to a 50% reduction in tail latency.
- Independent scaling of storage and compute, driving better infrastructure utilization and efficiency and providing unparalleled flexibility.
- Standards-based NVMe/TCP block storage access protocol for application servers to storage servers communication.
- LightOS clusters leverage standard NVMe 1.4 multipathing and offers data replications on storage target side, which provides transparency to the client with quick failover.
- Distributed and durable cluster management with fast failover handling.
- No single point of failure in data and control paths.
- Multiple LightOS clusters can exist in the same cloud data center and can be easily aggregated and managed as one large cloud-scale block storage solution.
Lightbits Labs Resources
- Deploying Reliable High Performance Storage with LightOS
- Meet Lightbits: Separation without Drama
- Lightbits Labs Named Storage Company of the Year (press release)
- LightOS and LightField announcement (press release)
For additional information, contact info@lightbitlabs.com
About Lightbits Labs™
Lightbits Labs, founded in 2016, is remaking modern cloud infrastructure on a global scale. The company’s mission is to reinvent the way storage and networking are conducted in data centers. As trailblazers in this field, its solutions are successfully being used in industry-leading private cloud and enterprise data centers around the globe. With strategic investors including Dell Technology Capital and Micron, and with investments from Chairman and co-founder Avigdor Willenz (Founder of Annapurna and Galileo), Lip-Bu Tan (CEO of Cadence and chairman of Walden International) and Marius Nacht (Co-Founder and Chairman of Check Point Software), Lightbits Labs is disaggregating storage and compute to improve performance and TCO. Learn more at www.lightbitslabs.com or contact us at info@lightbitslabs.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191211005163/en/
Contact information
Marianne Dempsey
On behalf of Lightbits Labs
mdempsey@rainierco.com
508-475-0025 ext. 115
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
KATE Launches "KABUKE: Break Convention" Kabuki-Inspired International Campaign17.7.2026 10:00:00 EEST | Press release
Global cosmetics brand KATE launched “KABUKE: Break Convention,” a new international campaign drawing on elements of Kabuki, the traditional Japanese performing art. The campaign debuted on Wednesday, July 8, 2026. In this campaign, KATE’s shadow enhancing makeup—rooted in Japanese aesthetics—was paired with the Kabuki spirit inherited from traditional Kabuki theater to communicate the value of individuality and self‑expression through makeup on a global scale. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260708829427/en/ KATE international campaign “KABUKE: Break Convention” key visual. Dedicated website: https://www.kate-global.net/my/special/kate_kabuki/ Since its founding, KATE has championed the slogan “NO MORE RULES.,” offering makeup that defies convention and empowers individuals to express their identity and bring out confidence. At the heart of this vision is the brand’s signature shadow enhancing makeup approach
Yoshihiro Shimamura Joins the Marché du Film’s “Investors Circle 2026” as an Invited Investor, Backing a New Feature Film17.7.2026 04:00:00 EEST | Press release
Shimamura Yoshihiro Film Production Co., Ltd. (Head office: Osaka, Japan; Representative Director: Yoshihiro Shimamura), a company active in film production and investment, today announced that Representative Director Yoshihiro Shimamura has decided to invest in an international feature film after being invited to the “Investors Circle 2026” — a distinction that reflects his standing as one of the field’s most highly regarded producers and investors. Hosted by the Marché du Film, the business arm of the Festival de Cannes and one of the world’s largest film markets, the Investors Circle is an invitation-only summit that connects a select group of private investors with high-end feature films during early-stage financing. Held in Cannes, France, May 16-17, 2026, it brings internationally acclaimed directors and producers together with investors around a curated slate of projects in development. During the summit, Shimamura attended private pitching sessions and, after individual meeting
Meiji Seika Pharma: Results from the Global Phase III Trial (Integral-2) of Nacubactam, a Novel β-Lactamase Inhibitor, Highlighted in The Lancet Microbe ’s Coverage of ESCMID Global Congress 202617.7.2026 04:00:00 EEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, President and Representative Director: Toshiaki Nagasato) today announced that results from the global Phase III trial (Integral-2) of nacubactam (Development Code: OP0595), a novel β-lactamase inhibitor, were highlighted in The Lancet Microbe’s coverage of ESCMID Global Congress 2026 (held in Munich, Germany). As highlighted in The Lancet Microbe’s coverage, the key findings presented by Meiji Seika Pharma at ESCMID Global Congress 2026 are as follows: The Integral-2 study (jRCT2031230076) is a global Phase III clinical trial that enrolled patients with complicated urinary tract infections, acute uncomplicated pyelonephritis, hospital-acquired bacterial pneumonia, ventilator-associated bacterial pneumonia, or complicated intra-abdominal infections caused by carbapenem-resistant Gram-negative bacteria (excluding Acinetobacter species). The study has achieved the prespecified study objectives. For the primary endpoint of overall treatme
Takeda’s Zasocitinib Demonstrates Consistent, High Rates of Skin Clearance Across the Body, Including Hard-to-Treat and High-Impact Sites, in Phase 3 Psoriasis Studies17.7.2026 01:00:00 EEST | Press release
Takeda (TSE:4502/NYSE:TAK) announced new data from the two pivotal Phase 3 studies of zasocitinib (TAK-279), a next-generation, highly selective and potent oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented at the 2026 American Academy of Dermatology (AAD) Innovation Academy, these secondary endpoint data show that zasocitinib demonstrated consistent and high rates of skin clearance across hard-to-treat, high-impact sites, including the scalp, nails, palms and soles, compared with placebo.1-5 These data build on the topline results from the Phase 3 randomized, multicenter, double-blind, placebo- and active comparator-controlled LATITUDE PsO 3001 and 3002 studies.2,6 In those studies, about 70% of patients treated with zasocitinib achieved static Physician Global Assessment (sPGA) 0/1 (clear or almost clear skin) at week 16, with a significantly greater Psoriasis Area and Severity Index (PASI) 75 response rate seen as early as w
Merz Completes Inaugural €450 Million Schuldschein Loan Issuance17.7.2026 00:36:00 EEST | Press release
The Merz Group has successfully completed its first-ever Schuldschein loan issuance, placing a total volume of €450 million in the debt capital market – a multiple of three relating to the launch volume. The debut transaction was significantly oversubscribed and attracted strong interest from all investor groups. The proceeds were settled and paid out today. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260716926041/en/ Dr. Almuth Steinkühler, Chief Financial Officer Merz Group The transaction comprises both fixed- and floating-rate tranches with maturities of three, five, seven, and ten years. Around 50 German and international investors participated, representing a broad range of institutions, including private banks, German federal state-owned banks, public savings banks, cooperative banks, pension funds and occupational pension institutions. With the successful placement, Merz has further diversified its funding base by
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom